RNA Analysis Market Size, Share & Trends Analysis Report By Product (Kits & Reagents, Services, Instruments), By Technology (qPCR, Sequencing), By End Use (CROs, Hospitals & Clinics), By Application, And Segment Forecasts, 2022 - 2030

Report Overview

The global RNA analysis market size was valued at USD 10.64 billion in 2021 and is anticipated to expand at a compound annual growth rate (CAGR) of 16.59% from 2022 to 2030. Transcriptomics is the study of the entire set of RNA transcripts present in a cell population to examine the gene expressions. Transcriptomics incorporates everything involving RNAs. Increased technological advancement activities in the field of transcriptomics and a rise in funding by numerous government and private organizations drive the growth of the industry. The COVID-19 pandemic has created abundant opportunities for industry players. For instance, in June 2020, NanoString Technologies, Inc. launched the nCounter Host Response Gene Expression Panel for the study of immune system response during COVID-19 virus research.

The product along with GeoMx Digital Spatial Profiler assisted the researchers in November 2021 study, to understand how COVID-19 did not infect olfactory sensory neurons in the patients. Similarly, in April 2021, Qiagen launched QIAseq DIRECT SARS-CoV-2 Kit, viral library preparation, and genome enrichment platform to reduce plastics use and library turnaround times when compared to primer-based sequencing. The company launched this product to cater to the increasing demand for high-throughput sequencing to carry out research and surveillance of novel and more hazardous variants of SARS-CoV-2.

The development and launch of novel products are anticipated to propel the industry growth as it assists CROs to enhance the quality of research and aid pharmaceutical & biotechnology companies in vaccination development. For instance, in March 2021, Rebus Biosystems launched the spatial transcriptomics analysis platform, the Rebus Esper, for spatial analysis of the transcriptome. This platform uses laser-powered optics for high-resolution images and allows researchers to analyze individual cells. Moreover, in recent years, the revolution in the research and clinical application of RNA-based techniques has increased.

The continuous development of the molecular technologies used for the analysis of transcriptomes and the implementation of next-generation sequencing platforms significantly changed the landscape of RNA research globally. RNA-seq is gaining an enormous role in the clinical care of cancer patients, as well as preclinical research. It allows an understanding of the molecular mechanisms underlying cancer, which has increased several clinical trials associated with transcriptome-based personalized oncology. Furthermore, the growing availability of transcriptome profiling allows for the introduction of transcriptomics in clinics.

Recently, numerous predictive and prognostic gene expression assays, along with cancer biomarkers, have been in use in clinical oncology. In addition, the change in the pattern of cancer classification-from clinical and histopathological to molecular opens a more personalized outlook for tumor therapy and diagnostics. The further development of transcriptome profiling will also allow for standardization and the reduction of its analysis cost, which will be the subsequent step for transcriptomics to become a standard of contemporary cancer medicine.

Technology Insights

On the basis of technologies, the global industry has been further divided into real time-PCR (qPCR), microarray, sequencing, and others. The real-time-PCR (qPCR) technology segment dominated the industry in 2021 and accounted for the maximum share of more than 43.00% of the global revenue. The high share was attributed to the wide usage of PCR for COVID-19 diagnostic across the globe. The qPCR technology is highly sensitive & quantitative and one of the most suitable methods for interrogating a comparatively small number of transcripts in a broad set of samples. PCR offers relatively high-sensitivity detection of SARS-CoV-2, evaluation of viral RNA in various types of clinical samples, detecting SARS-CoV-2 mutations, and evaluation of anti-SARS-CoV-2 drugs.

Thus, the COVID-19 pandemic served as a driving factor for industry growth. Also, quantitative Real-Time PCR is employed to conduct a comparative analysis of transcriptomes from the host and viral samples. Furthermore, sequencing is anticipated to witness substantial growth in the coming years owing to advancements in the next-generation and SMRT sequencing technology. The presence of several companies providing single-cell RNA sequencing services and the advent of bioinformatics algorithms are also driving the industry.

Product Insights

Based on products, the industry has been further sub-segmented into instruments, kits & reagents, and services. The kits & reagents products segment dominated the global market in 2021 and accounted for the maximum share of more than 59.10% of the overall revenue. Rising requirements for high-quality reagents and kits coupled with the repeated usage of reagents and media in transcriptome studies drive the growth of this segment. High-quality reagents and kits aid in delivering unmatched efficiency and strong performance ensure reliable and reproducible sequencing outcomes at a minimal cost.

Growing R&D activities in the pharmaceutical sector and increasing government investments in life science research are major factors expected to drivethe segment. NGS roots have begun with the adaptation of some SMART cDNA synthesis technology mainly for RNA-sequencing applications. In May 2021, Thermo Fisher Scientific, Inc. announced TaqPath SARS-CoV-2 CE-IVD RT-PCR Kit availability for international travel testing in the U.K. The kit is now entitled to clinics or laboratories in the surveillance. In addition, the PCR tests have been fundamental testing against SARS-CoV-2 in the United Kingdom since the inception of the pandemic.

Application Insights

The infectious diseases and pathogenesis application segment dominated the industry in 2021 and accounted for the largest share of more than 17.90% of the global revenue. The segment is estimated to expand further at the fastest CAGR during the forecast period. The identification of susceptible cells is crucial for understanding the pathogenic mechanism. Hence, there is increasing adoption of scRNA-sequencing to provide information about cell types susceptible to infection. Next-generation sequencing is transforming the health approach to infectious diseases and pathogenesis, as well as treating individuals.

Various methodologies have come for measuring gene expression and biomarkers for making their translation into clinical practice more feasible. The RNA structure and molecular dynamics segment is expected to register a significant CAGR from 2022 to 2030 as pharmaceutical importance for RNA in the development of a new drug are gradually increasing. In addition, molecular dynamics will also become a versatile tool to complement experimental investigations of RNA structural dynamics to provide opportunities for expanding the field and maximize gains from the molecular dynamic simulations, without any further methodological advances.

End-use Insights

The government institutes & academic centers segment reported the highest revenue share of more than 32.00% in 2021. The rising adoption rate of high throughput technologies for the effective process of RNA analysis by government institutes and academic centers drives the segment growth. Increasing applications of transcriptomics technologies in drug discovery are propelling the demand in the pharmaceutical as well as biotechnological industries. Similarly, research in drug discovery is also contributing to the market that is followed by clinical diagnostics. For instance, in April 2021, researchers developed TORNADO-seq, an RNA sequencing-based drug discovery platform to monitor the expression of the large gene for a detailed study of cellular phenotypes in organoids.

The Contract Research Organizations (CROs) segment is expected to grow at the fastest CAGR during the forecast period. Strategic activities by key market players support the segment growth. For instance, in Jan 2022, 10x Genomics announced the expansion of its 10x Certified Service Provider Network to incorporate three leading CROs. The CROs will partner with 10x Genomics to support leading biopharmaceutical companies seeking the advantage of 10x Genomics’ single-cell and spatial technologies to accelerate drug development and power novel therapeutic findings. The three CROs chosen for the 10x Genomics program are Azenta Life Sciences, Q2 Solutions, and CellCarta.

Regional Insights

North America accounted for the largest share of more than 42.80% in 2021. The growth is attributed to the rapid development of structure-based drug designs, increasing focus on transcriptomics research, and high investments in biopharmaceutical research and development. In addition, increasing investment in pharmaceutical research and drug development is the key factor that is accelerating the revenue growth of the companies in this region. However, Asia Pacific is projected to register the fastest CAGR during the forecast period. Growing investments by governments & enterprises are accelerating biotechnology research in the countries of Asia Pacific.

The Japanese government and non-government organizations are highly supportive of the growth of biotechnology research in the country and provide funds for research in the fields of medicine and life sciences. This encourages researchers to actively explore the transcriptomics space. Furthermore, increasing focus on APAC countries, owing to the low-cost manufacturing service, is expected to provide growth opportunities for the manufacturers. In addition, strategic activities, such as partnerships, will further augment the growth of this region. For instance, in January 2020, Genetron Holdings Ltd. entered into a strategic partnership agreement with Thermo Fisher Scientific to expand its precision cancer monitoring and diagnosis in China’s public hospitals.

Key Companies & Market Share Insights

The industry is highly fragmented with the presence of several small, mid, and large players that compete by adopting several organic growth strategies, such as product development and regional expansion, to enhance their industry presence. For instance, in May 2021, Bio-Rad Laboratories Inc. launched the latest offering of SEQuoia RiboDepletion Kit, for next-generation (NGS) sequencing, which can improve assessment efficiency by eradicating irrelevant rRNA fragments from the RNA sequencing library.Some of the key players in the global RNA analysis market include:

• Agilent Technologies, Inc.

• F. Hoffmann-La Roche AG

• Illumina, Inc.

• QIAGEN

• Thermo Fisher Scientific, Inc.

• Eurofins Scientific

• Merck KGaA

• Bio-Rad Laboratories, Inc.

• Pacific Bioscience of California, Inc.

• Affymetrix, Inc.

• Danaher Corp.

• Promega

RNA Analysis Market Report Scope

Global RNA Analysis Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research, Inc. has segmented the global RNA analysis market report based on technology, product, application, end-use, and region:

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Real Time-PCR (qPCR) Technology

  • Microarray Technology

  • Sequencing Technology

  • Others

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Instruments

  • Kits & Reagents

    • CHO Media miRNA & siRNA

    • Reverse Transcriptases & RT-PCR

    • RNA Extraction & Purification

    • RNA Interference

    • Others

  • Services

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Construction of RNA Expression Atlas

  • Epigenetics

  • Infectious Diseases&Pathogenesis

  • Alternative RNA Splicing

  • RNA Structure&Molecular Dynamics

  • Development &Delivery of RNA Therapeutics

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Government Institutes & Academic Centers

  • Pharmaceutical & Biotechnology Companies

  • Contract Research Organizations (CROs)

  • Hospitals & Clinics

• Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • Italy

    • Spain

    • France

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa

    • Saudi Arabia